US EditionPublished • loading... • Updated
Public Plans Shouldn’t Cover New Alzheimer’s Drug, Canada’s Drug Agency Recommends
Canada’s Drug Agency cites unclear benefits, safety risks, and high costs with projected public expenses up to $728 million by year three, limiting access primarily to wealthy patients.
Summary by The Globe & Mail
2 Articles
2 Articles
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
